EUVIMEDEUVIMED entdecken
Multizentrische Studie

Activité in vitro de la tigécycline vis-à-vis des germes pathogènes isolés d’infections respiratoires en Europe. Le Programme TEST 2004–2007

Y Rio, P Okamba, A Staal, J Didion, F Jurin, groupe d'étude TEST

Pathologie Biologie · 2009-02 · 57 (1) · 13-16

DOI: 10.1016/j.patbio.2008.08.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pathologie Biologie, 2009-02. Verfasst von Y Rio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de microbiologie, CHR de Metz-Thionville, site de Metz, 20 rue Drogon, 57000 Metz, France. y.rio@chr-metz-thionville.fr. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tigecycline (TGC), a semisynthetic glycylcycline, has a documented activity on Gram+ and Gram- pathogens including oxacillin-resistant (MRSA) and an extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Tigecycline Evaluation and Surveillance Trial (TEST) is an international surveillance study designed to assess the in vitro activity of TGC and 11 comparators against a range of important clinical pathogens from both the community and the hospital. The aim of this study was to assess efficacy of TGC, using this database, against pathogens implicated in community or hospital pneumonia and sinusitis. A total of 4163 isolates were consecutively collected in 21 European countries during three years (2004-2007). In all center, minimum inhibitory concentration (MIC) were determinated with the same Microscan panel (Dade-Behring). Tigecycline exhibited a good activity against respiratory pathogens, with the exception of Pseudomonas aeruginosa. Hundred percent of cocci Gram+ (Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus sp.) and 100% of Haemophilus sp. are inhibited with 0.5 mg/L, without effect of an associated beta-lactam resistance mechanism. TGC is active in vitro on 89% of Enterobacteriaceae, with MIC 90 less or equal to 2mg/L. Eighty-nine percent of Enterobacter sp. and 77% of Serratia sp. are susceptible with range of MIC 90 from 2 to 4 mg/L. These interesting results obtained in vitro are to be strengthened by clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteriaBacterial InfectionsBronchoalveolar Lavage FluidDrug EvaluationDrug Resistance, MicrobialEnterobacteriaceaeEuropeHaemophilusHumansIn Vitro TechniquesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMinocyclinePseudomonas aeruginosaRespiratory Tract InfectionsSpecies SpecificityStreptococcus pneumoniaeTigecycline

Substanzen

TigecyclineMinocycline

Autor:innen und Institutionen

  • Service de microbiologie, CHR de Metz-Thionville, site de Metz, 20 rue Drogon, 57000 Metz, France. y.rio@chr-metz-thionville.fr

Zitieren

APA

Rio, Y., Okamba, P., Staal, A., Didion, J., Jurin, F., & groupe d'étude TEST (2009). Activité in vitro de la tigécycline vis-à-vis des germes pathogènes isolés d’infections respiratoires en Europe. Le Programme TEST 2004–2007. Pathologie Biologie, 57(1), 13-16. https://doi.org/10.1016/j.patbio.2008.08.006

Vancouver

Rio Y, Okamba P, Staal A, Didion J, Jurin F, groupe d'étude TEST. Activité in vitro de la tigécycline vis-à-vis des germes pathogènes isolés d’infections respiratoires en Europe. Le Programme TEST 2004–2007. Pathologie Biologie. 2009;57(1):13-16. doi:10.1016/j.patbio.2008.08.006

BibTeX
@article{Rio2009,
  author = {Rio, Y and Okamba, P and Staal, A and Didion, J and Jurin, F and groupe d'étude TEST, groupe d'étude TEST},
  title = {Activité in vitro de la tigécycline vis-à-vis des germes pathogènes isolés d’infections respiratoires en Europe. Le Programme TEST 2004–2007},
  journal = {Pathologie Biologie},
  year = {2009},
  volume = {57},
  number = {1},
  pages = {13--16},
  doi = {10.1016/j.patbio.2008.08.006}
}
Kostenlos starten →